Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 Shares

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi bought 47,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were acquired at an average price of $0.71 per share, with a total value of $33,725.00. Following the transaction, the chief executive officer now directly owns 1,214,775 shares of the company’s stock, valued at $862,490.25. This represents a 4.07 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Krishna Vaddi also recently made the following trade(s):

• On Monday, December 30th, Krishna Vaddi bought 10,000 shares of Prelude Therapeutics stock. The shares were acquired at an average price of $1.20 per share, with a total value of $12,000.00.
• On Wednesday, December 18th, Krishna Vaddi purchased 100,000 shares of Prelude Therapeutics stock. The shares were purchased at an average price of $0.93 per share, with a total value of $93,000.00.

Prelude Therapeutics Stock Performance

Shares of Prelude Therapeutics stock opened at $0.74 on Friday. The stock has a market cap of $40.99 million, a price-to-earnings ratio of -0.42 and a beta of 1.43. The stock has a 50 day moving average price of $0.97 and a 200-day moving average price of $1.63. Prelude Therapeutics Incorporated has a one year low of $0.66 and a one year high of $6.80.

Prelude Therapeutics (NASDAQ:PRLD) last issued its quarterly earnings results on Monday, March 10th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.11. The business had revenue of $4.00 million for the quarter. Sell-side analysts predict that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, JMP Securities restated a “market outperform” rating and set a $4.00 price target (down previously from $7.00) on shares of Prelude Therapeutics in a report on Wednesday, December 11th.

Institutional Investors Weigh In On Prelude Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets bought a new stake in shares of Prelude Therapeutics during the 4th quarter worth approximately $26,000. Barclays PLC raised its position in Prelude Therapeutics by 86.0% during the 3rd quarter. Barclays PLC now owns 27,165 shares of the company’s stock valued at $57,000 after purchasing an additional 12,564 shares in the last quarter. XTX Topco Ltd bought a new stake in Prelude Therapeutics during the 3rd quarter valued at $100,000. JPMorgan Chase & Co. raised its position in Prelude Therapeutics by 925.0% during the 4th quarter. JPMorgan Chase & Co. now owns 61,149 shares of the company’s stock valued at $78,000 after purchasing an additional 55,183 shares in the last quarter. Finally, Walleye Capital LLC raised its position in Prelude Therapeutics by 446.2% during the 3rd quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after purchasing an additional 67,946 shares in the last quarter. 79.72% of the stock is owned by institutional investors.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.